Claes-Göran Östenson

Quick facts

Phase 2 pipeline

• ARA 290 · Diabetes
  ARA 290 is a peptide that acts as a glucagon receptor antagonist.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Claes-Göran Östenson portfolio CI brief
• Claes-Göran Östenson pipeline updates RSS